Semaglutide is beneficial in patients with HFpEF and obesity

Nature Reviews Cardiology, Published online: 14 September 2023; doi:10.1038/s41569-023-00935-6In patients with heart failure (HF) with preserved ejection fraction and obesity, treatment with the glucagon-like peptide 1 receptor agonist semaglutide (2.4 mg) leads to large reductions in HF-related symptoms and physical limitations, improves exercise function and decreases body weight compared with placebo, according to the STEP-HFpEF trial.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research